ARTICLE | Company News

EC approves Gilead's Zydelig

September 20, 2014 1:27 AM UTC

The European Commission approved Zydelig idelalisib from Gilead Sciences Inc. (NASDAQ:GILD) to treat chronic lymphocytic leukemia (CLL) and refractory follicular lymphoma (FL).

Gilead declined to disclose specific plans regarding the European launch timeline and price of the small molecule inhibitor of phosphoinositide 3-kinase (PI3K) delta. ...